| Not Yet Recruiting | Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cann NCT07441681 | NRG Oncology | Phase 3 |
| Recruiting | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN281 NCT06980038 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC NCT05423197 | Stanford University | Phase 2 |
| Not Yet Recruiting | Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell C NCT07535567 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 / Phase 3 |
| Not Yet Recruiting | A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs NCT07418034 | University of Maryland, Baltimore | Phase 2 |
| Suspended | Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer NCT06477003 | University of Oklahoma | N/A |
| Not Yet Recruiting | Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma NCT07507058 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Recruiting | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC NCT07462377 | EpiBiologics | Phase 1 |
| Not Yet Recruiting | CUE-101with Pembrolizumab for LA-HPV+HNSCCs NCT07172256 | Yale University | Phase 2 |
| Not Yet Recruiting | Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disea NCT07217028 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Not Yet Recruiting | Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Pos NCT07417605 | University Hospital, Brest | — |
| Recruiting | Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head NCT07445048 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 3 |
| Not Yet Recruiting | ABY-029 Head & Neck Trial NCT07279116 | Dartmouth-Hitchcock Medical Center | Phase 1 |
| Recruiting | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types NCT07503808 | IDEAYA Biosciences | Phase 1 |
| Not Yet Recruiting | H101 Plus TACE for r/m HNSCC NCT07398664 | West China Hospital | Phase 2 |
| Not Yet Recruiting | Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Adv NCT07432087 | Yue He, MD | Phase 3 |
| Not Yet Recruiting | Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell NCT07393477 | Sir Run Run Shaw Hospital | Phase 2 |
| Not Yet Recruiting | A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoin NCT07381075 | West China Hospital | Phase 2 |
| Not Yet Recruiting | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tu NCT07272642 | Radiopharm Theranostics, Ltd | Phase 1 |
| Recruiting | Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Re NCT07485296 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Recruiting | First in Human Study of SIM0610 in Solid Tumors NCT07348211 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregio NCT07333274 | Shandong Cancer Hospital and Institute | Phase 3 |
| Not Yet Recruiting | First in Human Study of QLS5316 in Solid Tumors NCT07358884 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer NCT07058805 | Olgun Elicin | Phase 2 |
| Not Yet Recruiting | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Nec NCT07216833 | Kyunghee Burkitt, DO, PhD | Phase 1 |
| Not Yet Recruiting | Blood Biomarkers Based Screening for HPV-driven OPC NCT06528353 | UNICANCER | N/A |
| Recruiting | Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial NCT06995508 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma NCT07254585 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 |
| Recruiting | A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Canc NCT07274852 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and NCT07232524 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors NCT07216105 | Fate Therapeutics | Phase 1 |
| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Recruiting | Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients NCT07514754 | Fondazione del Piemonte per l'Oncologia | N/A |
| Recruiting | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations NCT07109726 | Terremoto Biosciences Inc. | Phase 1 / Phase 2 |
| Withdrawn | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With An NCT05668949 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC NCT06989671 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 |
| Enrolling By Invitation | A Bidirectional Study of Individualized Postoperative Adjuvant Treatment Decision Model for Locally Advanced H NCT07532928 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043 | AstraZeneca | Phase 1 / Phase 2 |
| Withdrawn | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamo NCT05879484 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Al NCT07040956 | West China Hospital | Phase 2 |
| Not Yet Recruiting | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors NCT07036185 | Shanghai Bao Pharmaceuticals Co., Ltd. | Phase 1 |
| Active Not Recruiting | NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carc NCT06919666 | University of Colorado, Denver | Phase 1 / Phase 2 |
| Recruiting | High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Conc NCT06992427 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187 | Dren Bio | Phase 1 |
| Recruiting | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab H NCT06806852 | Boehringer Ingelheim | Phase 1 |
| Recruiting | A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck NCT07105592 | Fudan University | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers NCT06870487 | Pfizer | Phase 1 |
| Recruiting | Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients NCT06761937 | Erasmus Medical Center | Phase 1 |
| Not Yet Recruiting | Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers NCT05582590 | NexImmune Inc. | Phase 1 |
| Recruiting | A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-011 NCT06700070 | Pure Biologics S.A. | EARLY_Phase 1 |
| Recruiting | PDO Based Drug Sensitive Test in R/M HNSCC NCT06686342 | Huashan Hospital | — |
| Not Yet Recruiting | Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery NCT06815705 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N/A |
| Recruiting | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin a NCT06662058 | Emory University | N/A |
| Not Yet Recruiting | Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC NCT05065346 | Alpha Tau Medical LTD. | N/A |
| Recruiting | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863 | Clasp Therapeutics, Inc. | Phase 1 |
| Recruiting | Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC NCT06855212 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Rega NCT06727565 | Gilead Sciences | Phase 2 |
| Recruiting | Heavy Strength Training in Head and Neck Cancer Survivors NCT06289049 | University of Alberta | Phase 2 |
| Not Yet Recruiting | Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care NCT06814067 | Fudan University | Phase 2 |
| Active Not Recruiting | Longitudinal Oral Health Changes After Head and Neck Radiotherapy NCT07394842 | Ain Shams University | — |
| Recruiting | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors NCT06789172 | Epkin | Phase 1 |
| Not Yet Recruiting | Surgery and Reducing Ionizing Radiation of the Unknown Primary NCT06578871 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 |
| Recruiting | Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas NCT06540443 | MegaPro Biomedical Co. Ltd. | Phase 1 |
| Recruiting | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors NCT06747585 | Alentis Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy f NCT06532279 | NRG Oncology | Phase 2 |
| Recruiting | PET-imaging of Two Vartumabs in Patients With Solid Tumors NCT06645808 | Var2 Pharmaceuticals | EARLY_Phase 1 |
| Recruiting | Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC NCT06693323 | University of California, Irvine | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC NCT06699498 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluati NCT06914999 | Emory University | EARLY_Phase 1 |
| Recruiting | Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC NCT06725498 | Beijing Tongren Hospital | Phase 2 |
| Not Yet Recruiting | Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCC NCT06694350 | Zhejiang Provincial People's Hospital | Phase 2 |
| Recruiting | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers NCT06422403 | National University Hospital, Singapore | Phase 2 |
| Recruiting | Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M NCT07448727 | University of Rome Tor Vergata | — |
| Recruiting | Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) NCT06648096 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Phase 1 / Phase 2 |
| Recruiting | A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With NCT06668961 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cel NCT06601335 | Akeso | Phase 3 |
| Recruiting | Thermotherapy in Addition to SOC Palliative Radiotherapy NCT06659146 | King's College London | N/A |
| Recruiting | Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma NCT06194656 | Shanghai Institute Of Biological Products | Phase 2 |
| Recruiting | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC NCT06597565 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head a NCT06525220 | Merus B.V. | Phase 3 |
| Recruiting | GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients NCT07511413 | Fondazione del Piemonte per l'Oncologia | — |
| Recruiting | Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma NCT06308913 | University of Wisconsin, Madison | EARLY_Phase 1 |
| Recruiting | A Study of VET3-TGI in Patients With Solid Tumors NCT06444815 | KaliVir Immunotherapeutics | Phase 1 |
| Recruiting | Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and NCT06575322 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Recruiting | Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Functio NCT06576180 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Recruiting | The Value of CEUS in Assessing the Response of Cervical Lymph Nodes After NACI for HNSCC NCT06727162 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Active Not Recruiting | A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Hea NCT07435324 | R-Pharm | Phase 3 |
| Not Yet Recruiting | A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in t NCT06509997 | Lei Liu | Phase 2 |
| Recruiting | A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSC NCT06163534 | Tempus AI | — |
| Not Yet Recruiting | AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC NCT06508606 | West China Hospital | Phase 2 |
| Recruiting | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours NCT06147037 | AstraZeneca | Phase 1 |
| Recruiting | AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy NCT06494995 | Fudan University | Phase 2 |
| Active Not Recruiting | CD40 Agonist and PD-1 Inhibitor in HNSCC NCT06159621 | University of Pennsylvania | Phase 1 |
| Recruiting | A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Ne NCT06444009 | Lei Liu | Phase 2 |
| Recruiting | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging NCT03865277 | Technische Universität Dresden | Phase 2 |
| Recruiting | Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC NCT06494943 | Fudan University | Phase 1 / Phase 2 |
| Recruiting | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated NCT06496178 | Merus B.V. | Phase 3 |
| Recruiting | A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) NCT06378177 | Lyvgen Biopharma Holdings Limited | Phase 2 |
| Active Not Recruiting | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or M NCT06082167 | Exelixis | Phase 2 / Phase 3 |
| Recruiting | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous C NCT06437522 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Withdrawn | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck NCT06357858 | Case Comprehensive Cancer Center | Phase 1 |
| Recruiting | PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, NCT06366451 | Presage Biosciences | EARLY_Phase 1 |
| Recruiting | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatmen NCT06451497 | Zumutor Biologics Inc. | Phase 1 |
| Recruiting | Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis NCT06905145 | National Cancer Institute, Naples | — |
| Completed | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors NCT06273852 | Pure Biologics S.A. | EARLY_Phase 1 |
| Not Yet Recruiting | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors NCT06383507 | Zhejiang University | Phase 1 |
| Not Yet Recruiting | Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ H NCT06366945 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an NCT05576974 | University of Texas Southwestern Medical Center | Phase 2 |
| Withdrawn | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carbopl NCT06084845 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Active Not Recruiting | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma NCT06332092 | Fulgent Pharma LLC. | Phase 2 |
| Recruiting | Dose Escalation Using Hypoxia-adjusted Radiotherapy NCT06087614 | Rajiv Gandhi Cancer Institute & Research Center, India | Phase 2 |
| Recruiting | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours NCT06305247 | Ipsen | Phase 1 / Phase 2 |
| Terminated | FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer NCT06338657 | University of Southern California | Phase 1 |
| Enrolling By Invitation | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors NCT06690216 | Man Hu | Phase 1 / Phase 2 |
| Recruiting | Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically N NCT06323369 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies NCT06150664 | Compass Therapeutics | Phase 1 |
| Recruiting | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SA NCT06088381 | University of Maryland, Baltimore | Phase 2 |
| Active Not Recruiting | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors NCT06238479 | Eli Lilly and Company | Phase 1 |
| Recruiting | a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in H NCT06248996 | Lund University Hospital | Phase 3 |
| Completed | A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing NCT06251050 | West China Hospital | Phase 1 / Phase 2 |
| Recruiting | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Ne NCT05913388 | Providence Health & Services | Phase 2 |
| Recruiting | PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC NCT06239220 | Glenn J. Hanna | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma NCT06199271 | Zhongzheng Xiang | Phase 2 |
| Recruiting | Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot St NCT06162377 | M.D. Anderson Cancer Center | Phase 4 |
| Withdrawn | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung NCT05412875 | Ohio State University Comprehensive Cancer Center | N/A |
| Recruiting | ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors NCT06007729 | Hansoh BioMedical R&D Company | Phase 2 |
| Recruiting | Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). NCT05977907 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy NCT06183268 | Covenant Health Cancer Center | N/A |
| Recruiting | Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC NCT06170710 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | A Study of Adaptive Radiotherapy of Head-neck Cancer Using Daily Replanning and Optimization of the Treatment NCT07506902 | Rigshospitalet, Denmark | N/A |
| Unknown | Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma NCT06142318 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Active Not Recruiting | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid NCT06084481 | AbbVie | Phase 1 |
| Active Not Recruiting | Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had S NCT05540899 | American College of Radiology | Phase 1 |
| Recruiting | Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squam NCT05784012 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Meta NCT06047379 | Neonc Technologies, Inc. | Phase 1 / Phase 2 |
| Recruiting | HRYZ-T101 Injection for HPV18 Positive Solid Tumor NCT05952947 | HRYZ Biotech Co. | Phase 1 |
| Recruiting | Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas NCT06109207 | West China Hospital | Phase 1 |
| Recruiting | Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC NCT06081673 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 |
| Recruiting | Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy NCT05793151 | Medical University of South Carolina | N/A |
| Terminated | Study of ALE.C04 in Patients With Head and Neck Cancer NCT06054477 | Alentis Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squam NCT06006169 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC NCT05993858 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer NCT05902988 | Volastra Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in NCT06022029 | OncoNano Medicine, Inc. | Phase 1 |
| Recruiting | Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer NCT05945875 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Recruiting | Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC NCT06100497 | Beijing Tongren Hospital | Phase 2 |
| Not Yet Recruiting | Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck NCT06016413 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer NCT05901545 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Recruiting | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Sol NCT05983432 | SystImmune Inc. | Phase 1 |
| Unknown | Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma NCT05965154 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Recruiting | HN-QUEST: A Study of Head and Neck Imaging Biomarkers NCT05919290 | University Health Network, Toronto | N/A |
| Active Not Recruiting | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous NCT05909904 | BeiGene | Phase 2 |
| Unknown | Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinom NCT06011993 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Unknown | Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous NCT06023875 | Xuekui Liu | Phase 2 |
| Recruiting | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Posit NCT05877599 | AstraZeneca | Phase 1 |
| Active Not Recruiting | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors NCT05858736 | OncoC4, Inc. | Phase 1 |
| Unknown | Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant NCT05964595 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Withdrawn | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer P NCT04987996 | Providence Health & Services | Phase 2 |
| Recruiting | 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the NCT05674396 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid NCT04969315 | Portage Biotech | Phase 1 / Phase 2 |
| Terminated | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and NCT05551117 | MacroGenics | Phase 2 |
| Terminated | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors NCT05563272 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 2 |
| Active Not Recruiting | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors NCT05867303 | RemeGen Co., Ltd. | Phase 1 |
| Active Not Recruiting | Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC NCT05433116 | Universität des Saarlandes | Phase 2 |
| Recruiting | Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC NCT05726370 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy NCT05996432 | Vanderbilt-Ingram Cancer Center | EARLY_Phase 1 |
| Recruiting | A Study of the Use of Fat Flap Reconstruction to Reduce Neck Injury After Cancer Treatment NCT05889091 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinom NCT05747625 | Eben Rosenthal | Phase 1 |
| Recruiting | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of NCT06102395 | Beijing Tongren Hospital | Phase 3 |
| Recruiting | Arabic PRO Measures for Head and Neck Cancer Radiotherapy. NCT06662929 | King Saud University | — |
| Recruiting | The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR NCT05854823 | Fifth Affiliated Hospital, Sun Yat-Sen University | N/A |
| Unknown | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor NCT05787535 | HRYZ Biotech Co. | Phase 1 |
| Recruiting | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors NCT05784688 | TiumBio Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours NCT05714553 | NuCana plc | Phase 1 / Phase 2 |
| Active Not Recruiting | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After An NCT05222932 | TILT Biotherapeutics Ltd. | Phase 1 |
| Recruiting | Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head an NCT05526924 | University of Chicago | Phase 1 |
| Recruiting | PET/CT Follow up for Head and Neck Squamous Cell Carcinoma NCT05707078 | Rigshospitalet, Denmark | N/A |
| Unknown | Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NCT06307093 | R-Pharm | Phase 1 |
| Recruiting | Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC NCT05941338 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Withdrawn | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head NCT05472506 | Ikena Oncology | Phase 1 |
| Unknown | Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma NCT06170697 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Real-time Margin Assessment in Head and Neck Cancer NCT05499065 | University Medical Center Groningen | Phase 2 |
| Recruiting | Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma NCT05183048 | University of Alabama at Birmingham | EARLY_Phase 1 |
| Recruiting | Liquid Biopsy for Early DiagNosis of Squamous Cell Carcinoma of the HeAd and NeCk rEgion NCT05645783 | Royal Marsden NHS Foundation Trust | — |
| Active Not Recruiting | 3D Specimen Maps for RT Planning NCT05743569 | Vanderbilt University Medical Center | — |
| Terminated | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors NCT05576077 | Turnstone Biologics, Corp. | Phase 1 |
| Terminated | The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients With Head and Neck Can NCT05457478 | OHSU Knight Cancer Institute | N/A |
| Completed | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors NCT05538572 | Prelude Therapeutics | Phase 1 |
| Recruiting | Study of CHS-114 in Participants With Advanced Solid Tumors NCT05635643 | Coherus Oncology, Inc. | Phase 1 |
| Completed | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizum NCT05585034 | Xencor, Inc. | Phase 1 |
| Active Not Recruiting | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas NCT05565417 | Immunitas Therapeutics | Phase 1 / Phase 2 |
| Suspended | A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer NCT05420948 | University of Chicago | Phase 2 |
| Active Not Recruiting | Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Me NCT05338905 | Roswell Park Cancer Institute | N/A |
| Recruiting | HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC NCT05364411 | Joris B.W. Elbers | N/A |
| Recruiting | Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC NCT05437380 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N/A |
| Terminated | A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma NCT05322135 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Recruiting | A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer NCT05544136 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC NCT05516589 | West China Hospital | Phase 2 |
| Recruiting | Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC NCT05446467 | Zhejiang Provincial People's Hospital | Phase 2 |
| Withdrawn | ITIL-168 in Advanced Solid Tumors NCT05393635 | Instil Bio | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) NCT05172258 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease NCT05229614 | CNAO National Center of Oncological Hadrontherapy | Phase 2 |
| Terminated | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; NCT05432193 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Phase 1 |
| Completed | Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck C NCT05936502 | Head and Neck Cancer International Group | — |
| Unknown | Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC NCT05351762 | Xijing Hospital | Phase 2 |
| Withdrawn | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) NCT04831450 | University of Miami | Phase 2 |
| Active Not Recruiting | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders NCT05286294 | Oslo University Hospital | Phase 2 |
| Completed | PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or NCT06413095 | Presage Biosciences | EARLY_Phase 1 |
| Unknown | SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome NCT05400239 | Guy's and St Thomas' NHS Foundation Trust | — |
| Unknown | BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcin NCT05299203 | West China Hospital | Phase 1 |
| Unknown | Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer NCT05294900 | Yonsei University | Phase 2 |
| Terminated | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours NCT05363605 | Fusion Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Terminated | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors NCT05229601 | HiFiBiO Therapeutics | Phase 1 |
| Recruiting | HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to E NCT05280457 | Yonsei University | Phase 2 |
| Completed | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCH NCT05077709 | IO Biotech | Phase 2 |
| Unknown | Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the NCT05189184 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Withdrawn | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and NCT05220748 | Rakuten Medical, Inc. | Phase 1 |
| Unknown | Effect of Accelerated RTH in Squamous Cell Carcinoma in Head and Neck NCT05291663 | Assiut University | — |
| Active Not Recruiting | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced So NCT05238883 | HiFiBiO Therapeutics | Phase 1 |
| Recruiting | The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advan NCT05343325 | Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 2 |
| Recruiting | Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC NCT05272696 | Guangdong Provincial People's Hospital | Phase 2 |
| Active Not Recruiting | Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable NCT05286060 | Yonsei University | Phase 2 |
| Active Not Recruiting | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors NCT05239143 | Poseida Therapeutics, Inc. | Phase 1 |
| Recruiting | Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality NCT05031910 | Thomas Jefferson University | N/A |
| Terminated | RTX-224 Monotherapy in Patients With Solid Tumors NCT05219578 | Rubius Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) NCT04938609 | Providence Health & Services | Phase 2 |
| Unknown | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tum NCT05117138 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC NCT05213884 | Chongqing University Cancer Hospital | Phase 2 |
| Completed | Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherap NCT05918224 | West China Hospital | Phase 2 |
| Active Not Recruiting | A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC NCT05054439 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Active Not Recruiting | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors NCT05145907 | TJ Biopharma Co., Ltd. | Phase 2 |
| Withdrawn | Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients NCT05099952 | Roswell Park Cancer Institute | N/A |
| Unknown | The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors NCT05821751 | Fondazione del Piemonte per l'Oncologia | N/A |
| Unknown | Correlation of Fecal Microbiome and Its Metabolites With Outcome of Radiotherapy in Head and Neck Carcinoma NCT05156177 | Institute of Oncology Ljubljana | — |
| Unknown | Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM NCT05136768 | Jun-Lin Yi, MD | Phase 2 |
| Active Not Recruiting | Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma NCT05522985 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurren NCT05047094 | Alpha Tau Medical LTD. | N/A |
| Recruiting | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Hea NCT05005403 | AbbVie | Phase 1 |
| Active Not Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic H NCT05044897 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) NCT05044117 | Sun Yat-sen University | Phase 3 |
| Recruiting | A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674 | Nurix Therapeutics, Inc. | Phase 1 |
| Unknown | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents NCT05094804 | OncoResponse, Inc. | Phase 1 / Phase 2 |
| Terminated | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma NCT04854499 | Gilead Sciences | Phase 2 |
| Unknown | Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical NCT05065086 | Royal Marsden NHS Foundation Trust | — |
| Active Not Recruiting | Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or NCT04946968 | National Cancer Centre, Singapore | Phase 2 |
| Unknown | Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surge NCT05024019 | Eye & ENT Hospital of Fudan University | Phase 2 |
| Unknown | Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell NCT05075122 | Martin-Luther-Universität Halle-Wittenberg | Phase 2 |
| Unknown | PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT NCT05008796 | Chang Gung Memorial Hospital | — |
| Unknown | SPIO-enhanced MRI in Oral Cancer for Sentinel Lymph Node Identification NCT04803331 | Radboud University Medical Center | N/A |
| Completed | PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC NCT06062602 | Presage Biosciences | EARLY_Phase 1 |
| Unknown | Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 NCT04999800 | Shi Yuankai | Phase 2 |
| Recruiting | Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC ( NCT04807140 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Completed | Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patien NCT04752384 | Medical College of Wisconsin | Phase 2 |
| Active Not Recruiting | MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients NCT04651634 | MitoImmune Therapeutics | Phase 2 |
| Unknown | Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma NCT05143268 | Lorenzo Livi | — |
| Active Not Recruiting | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT04843098 | Suzhou Junde Biotechnology Co., Ltd | Phase 1 / Phase 2 |
| Terminated | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma NCT04762225 | Repertoire Immune Medicines | Phase 1 |
| Active Not Recruiting | Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck NCT04675333 | ALX Oncology Inc. | Phase 2 |
| Recruiting | Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China NCT04857164 | Yuankai Shi | Phase 2 |
| Active Not Recruiting | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and NCT04868877 | Merus B.V. | Phase 1 / Phase 2 |
| Completed | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors NCT04721223 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca NCT04848116 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Terminated | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic NCT04624113 | Washington University School of Medicine | Phase 1 |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Active Not Recruiting | Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Ca NCT04675294 | ALX Oncology Inc. | Phase 2 |
| Unknown | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC NCT04826679 | Sun Yat-sen University | Phase 2 |
| Terminated | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer NCT04634825 | MacroGenics | Phase 2 |
| Completed | Evaluation of OE-MRI in Patients With H&N Cancer NCT04724096 | Nottingham University Hospitals NHS Trust | — |
| Withdrawn | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advance NCT04464967 | NKGen Biotech, Inc. | Phase 1 / Phase 2 |
| Recruiting | Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC NCT04681469 | Gruppo Oncologico del Nord-Ovest | Phase 2 |
| Unknown | Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China NCT04740996 | Shi Yuankai | — |
| Recruiting | A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer NCT04722523 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma NCT05476965 | Hubei Cancer Hospital | Phase 2 |
| Recruiting | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid NCT03740256 | Baylor College of Medicine | Phase 1 |
| Unknown | The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs NCT05202275 | Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associ NCT04564989 | UNC Lineberger Comprehensive Cancer Center | — |
| Active Not Recruiting | Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck C NCT04452032 | Jules Bordet Institute | Phase 2 |
| Completed | A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention NCT05523323 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors NCT04616196 | Nektar Therapeutics | Phase 1 / Phase 2 |
| Completed | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locati NCT04357873 | UNICANCER | Phase 2 |
| Active Not Recruiting | Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinom NCT04599309 | University Health Network, Toronto | — |
| Unknown | 18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck NCT04196985 | Turku University Hospital | N/A |
| Completed | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and NCT04452214 | Cantargia AB | Phase 1 |
| Recruiting | Specific Methylation Profiles in HNSCC NCT04567056 | Aalborg University Hospital | — |
| Completed | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer NCT04555837 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients NCT04414540 | Trisha Wise-Draper | Phase 2 |
| Completed | Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and NCT04694846 | Thomas Jefferson University | N/A |
| Terminated | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors NCT04442126 | Numab Therapeutics AG | Phase 1 / Phase 2 |
| Unknown | Sodium Selenite Supplementation in Patients With Head and Neck Cancer NCT05451576 | Chang Gung Memorial Hospital | N/A |
| Unknown | Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Ci NCT04523883 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 |
| Unknown | Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tu NCT04297995 | Shanghai Henlius Biotech | Phase 2 |
| Completed | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China NCT04121286 | Allist Pharmaceuticals, Inc. | Phase 1 |
| Active Not Recruiting | HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Sq NCT04369937 | Dan Zandberg | Phase 2 |
| Recruiting | Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer NCT04375384 | Wake Forest University Health Sciences | Phase 2 |
| Completed | A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable NCT07435311 | R-Pharm | Phase 1 |
| Active Not Recruiting | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab NCT04074967 | Dan Zandberg | Phase 1 / Phase 2 |
| Unknown | Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma NCT04440917 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 |
| Recruiting | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven NCT04429542 | Bicara Therapeutics | Phase 1 |